ATLANTA--(BUSINESS WIRE)--Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyro
Full Story >>
Vote
+8